Skip to main content

Advertisement

SpringerLink
Log in

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Despite advances in treatment of patients with metastatic breast cancer (MBC), prognosis remains poor and median survival is 2–3 years. Resistance to antineoplastics mediated by many factors, potentially including overexpression of drug efflux proteins or altered β-tubulin isotype expression limits the effectiveness of MBC chemotherapy. Capecitabine, approved for anthracycline- and taxane-resistant MBC, has produced modest responses, highlighting the need for more effective treatments for MBC resistant to multiple chemotherapeutic agents. Agents with potential to reverse drug resistance have not proven effective. Albumin-bound paclitaxel is a formulation that may enhance delivery to tumor tissues. Conversely, ixabepilone, an epothilone analog, has been reported to have lower susceptibility to at least some mechanisms of tumor resistance and clinical activity in resistant/refractory MBC. The topoisomerase-I inhibitor irinotecan also has low cross-resistance with other antineoplastics, and has shown some activity against refractory MBC. Development of new agents and identification of genetic biomarkers in translational studies promise to improve management of patients with resistant/refractory breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics, 2008. Available via CA Cancer J Clin. http://caoline.amcancersoc.org/cgi/content/full/CA.2007.0010v1. Accessed 5 Mar 2008

  2. Ries LAG, Melbert D, Krapcho M et al (eds) (2006) SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004. Accessed 11 Feb 2008

  3. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617–632

    Article  PubMed  Google Scholar 

  4. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  PubMed  CAS  Google Scholar 

  5. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  6. NCCN (2008) Breast cancer; clinical practice guidelines in oncology - v.2. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 11 Feb 2008

  7. Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760–1775

    Article  PubMed  CAS  Google Scholar 

  8. Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin Oncol 17:3362–3365

    PubMed  CAS  Google Scholar 

  9. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52

    Article  PubMed  Google Scholar 

  10. Bonneterre J, Dieras V, Tubiana-Hulin M et al (2004) Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91:1466–1471

    PubMed  CAS  Google Scholar 

  11. Ishikawa T, Shimizu S, Inaba M et al (2004) A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer. Breast Cancer 11:374–379

    Article  PubMed  Google Scholar 

  12. Vassilomanolakis M, Koumakis G, Barbounis V et al (2005) First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 14:136–141

    Article  PubMed  CAS  Google Scholar 

  13. Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12:1639–1647

    PubMed  CAS  Google Scholar 

  14. Gottesman M (2002) Mechanisms of cancer drug resistance. Ann Rev Med 53:615–627

    Article  PubMed  CAS  Google Scholar 

  15. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6:71–84

    Article  PubMed  CAS  Google Scholar 

  16. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302

    Article  PubMed  CAS  Google Scholar 

  17. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411–424

    Article  PubMed  CAS  Google Scholar 

  18. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    Article  PubMed  CAS  Google Scholar 

  19. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073–10080

    PubMed  CAS  Google Scholar 

  20. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

    Article  PubMed  CAS  Google Scholar 

  21. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC (2000) BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 60:831–837

    Article  PubMed  CAS  Google Scholar 

  22. Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917–931

    Article  PubMed  CAS  Google Scholar 

  23. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73

    Article  PubMed  CAS  Google Scholar 

  24. Kavallaris M (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs 8:17–25

    Article  PubMed  CAS  Google Scholar 

  25. Honjo Y, Hrycyna CA, Yan QW et al (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639

    PubMed  CAS  Google Scholar 

  26. Verrills NM, Kavallaris M (2005) Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. Curr Pharm Des 11:1719–1733

    Article  PubMed  CAS  Google Scholar 

  27. Paradiso A, Mangia A, Chiriatti A et al (2005) Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16(suppl. 4):iv14–iv19

    Article  PubMed  Google Scholar 

  28. Kamath K, Wilson L, Cabral F, Jordan MA (2005) ßIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280:12902–12907

    Article  PubMed  CAS  Google Scholar 

  29. Zhu H, Guo W, Zhang L et al (2005) Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4:451–456

    Article  PubMed  CAS  Google Scholar 

  30. Brooks T, Minderman H, O’Loughlin KL et al (2003) Taxane-based reversal agents modulate drug resistance mediated by p-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195–1205

    PubMed  CAS  Google Scholar 

  31. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165

    PubMed  Google Scholar 

  32. Menefee M, Fan C, Edgerly M et al (2005) Tariquidar (XR9576) is a potent and effective p-glycoprotein (pgp) inhibitor that can be administered safely with chemotherapy. J Clin Oncol 23:16S Abstract 3093

    Google Scholar 

  33. Pusztai L, Wagner P, Ibrahim N et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–691

    Article  PubMed  CAS  Google Scholar 

  34. Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542

    Article  PubMed  CAS  Google Scholar 

  35. Xeloda tablets [package insert] (2006) Nutley, NJ: Roche Pharmaceuticals

  36. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

    PubMed  CAS  Google Scholar 

  37. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56–64

    Article  PubMed  CAS  Google Scholar 

  38. Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768

    Article  PubMed  CAS  Google Scholar 

  39. Reichardt P, von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233

    Article  PubMed  CAS  Google Scholar 

  40. Wist EA, Sommer HH, Østenstad B, Risbert T, Bremnes Y, Mjaaland I (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186–189

    Article  PubMed  Google Scholar 

  41. Petit T, Benider A, Yovine A et al (2006) Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 17:337–343

    Article  PubMed  CAS  Google Scholar 

  42. Zelek L, Cottu P, Tubiana-Hulin M et al (2002) Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20:2551–2558

    Article  PubMed  CAS  Google Scholar 

  43. Perez EA (2004) Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 4:S113–S116

    Article  PubMed  CAS  Google Scholar 

  44. Burch PA, Mailliard JA, Hillman DW et al (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group trial. Am J Clin Oncol 28:195–200

    Article  PubMed  CAS  Google Scholar 

  45. Seo JH, Oh SC, Choi CW et al (2007) Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59:269–274

    Article  PubMed  CAS  Google Scholar 

  46. Blum JL, Savin MA, Edelman G et al (2004) Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol 22:14S Abstract 543

    Google Scholar 

  47. Dieras V, Valero V, Limentani S et al (2005) Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): final results. J Clin Oncol 23:16S Abstract 565

    Google Scholar 

  48. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  PubMed  CAS  Google Scholar 

  49. Capecitabine and paclitaxel (albumin-stabilized nanoparticle formulation) in treating women undergoing surgery for stage II or stage III breast cancer. http://clinicaltrials.gov/ct2/show/NCT00397761. Accessed 8 Feb 2008

  50. Chemotherapy, G-CSF, and ABI-007 with or without trastuzumab in treating women with high-risk localized breast cancer. http://clinicaltrials.gov/ct2/show/NCT00407888. Accessed 8 Feb 2008

  51. Paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, and gemcitabine as first-line therapy in treating patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00503906. Accessed 8 Feb 2008

  52. Combination study of a new taxane and capecitabine in patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00327743. Accessed 8 Feb 2008

  53. Study of larotaxel 90 mg/m2 or docetaxel every 3 weeks, alone or with trastuzumab according to Her2/neu status, after combination of anthracycline and cyclophosphamide as preoperative therapy in patients with high risk localized breast cancer. http://clinicaltrials.gov/ct2/show/NCT00485979. Accessed 3 Mar 2008

  54. Study of larotaxel in combination with weekly herceptin® in patients with HER2 positive metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00387907. Accessed 8 Feb 2008

  55. O’Shaughnessy JA, Clark RS, Blum JL et al (2005) Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6:143–149

    Article  PubMed  CAS  Google Scholar 

  56. Vukelja S, O’Shaughnessy J, Campos S et al (2005) Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: phase 2 study results. J Clin Oncol 23:16S Abstract 562

    Google Scholar 

  57. Perez EA, Hillman DW, Mailliard JA et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849–2855

    Article  PubMed  CAS  Google Scholar 

  58. Perez EA, Lerzo G, Pivot X et al (2007) Efficacy and safety of ixabepilone (BMS–247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407–3414

    Article  PubMed  CAS  Google Scholar 

  59. Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS–247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437

    PubMed  CAS  Google Scholar 

  60. Bollag DM, McQueney PA, Zhu J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325–2333

    PubMed  CAS  Google Scholar 

  61. Chin YW, Balunas MJ, Chai HB, Kinghorn AD (2006) Drug discovery from natural resources. AAPS J 8:E239–E253

    PubMed  CAS  Google Scholar 

  62. Giannakakou P, Gussio R, Nogales E et al (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97:2904–2909

    Article  PubMed  CAS  Google Scholar 

  63. Giannakakou P, Sackett DL, Kang YK et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant ß-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125

    Article  PubMed  CAS  Google Scholar 

  64. Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271–280

    Article  PubMed  CAS  Google Scholar 

  65. Zhou Y, Zhong Z, Liu F et al (2005) KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Amer Assoc Cancer Res 46: Abstract 2535

  66. Jordan MA, Miller H, Ni L et al (2006) The Pat-21 breast cancer model derived from a patient with primary taxol® resistance recapitulates the phenotype of its origin has altered beta-tubulin expression and is sensitive to ixabepilone. The 97th AACR Annual Meeting, Washington DC, April 1–5, 2006 Abstract LB-280

  67. Thomas E, Tabernero J, Fornier M et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399–3406

    Article  PubMed  CAS  Google Scholar 

  68. Valero V, Jones SE, Von Hoff DD et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362–3368

    PubMed  CAS  Google Scholar 

  69. Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Mayo College of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Edith A. Perez

Authors
  1. Edith A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edith A. Perez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perez, E.A. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114, 195–201 (2009). https://doi.org/10.1007/s10549-008-0005-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0005-6

Keywords

Search

Navigation